非维生素K拮抗剂口服抗凝药相关脑出血的凝血检测
该研究基于前瞻性多中心RASUNOA注册研究,纳入2012年2月至2014年12月间21个中心的61例NOAC相关脑出血患者,分析药物特异性凝血检测(抗Xa因子检测、稀释凝血酶时间)和非特异性检测(INR、aPTT、凝血酶时间)的使用频率,并探讨入院时抗凝强度与血肿体积及血肿扩大的关联。结果显示,仅16例(26%)进行了药物特异性凝血检测,仅29%的中心使用药物特异性检测;部分病例INR和aPTT正常但药物浓度处于峰值范围;在有药物特异性浓度数据的患者中,50%入院时药物水平处于峰值范围;较高的抗凝强度与入院时血肿体积或后续血肿扩大无关联。结论提示药物特异性检测使用不足,非特异性凝血正常不能排除峰值浓度,入院抗凝强度不预测血肿体积或扩大。
要点
- 在61例NOAC相关脑出血患者中,仅16例(26%)进行了药物特异性凝血检测,仅29%的中心使用药物特异性检测。
- 部分病例INR和aPTT正常,但药物浓度处于峰值范围,非特异性凝血正常不能可靠排除峰值浓度。
- 在有药物特异性浓度数据的患者中,50%入院时药物水平处于峰值范围。
- 较高的抗凝强度与入院时血肿体积或后续血肿扩大无关联。
- 入院时抗凝强度不预测基线血肿体积或后续血肿扩大。
适用人群与场景
- NOAC相关脑出血患者,来自前瞻性多中心RASUNOA注册研究,2012年2月至2014年12月间在21个中心纳入。
研究设计与关键结果
- 研究类型:前瞻性多中心注册研究(RASUNOA注册研究),纳入61例NOAC相关脑出血患者,来自21个中心。
- 药物特异性凝血检测(抗Xa因子检测、稀释凝血酶时间)在16例(26%)中进行,仅29%的中心使用药物特异性检测。
- 部分病例INR和aPTT正常,但药物浓度处于峰值范围。
- 在有药物特异性浓度数据的患者中,50%入院时药物水平处于峰值范围。
- 较高的抗凝强度与入院时血肿体积或后续血肿扩大无关联。
证据类型、等级与局限
- 证据类型:前瞻性多中心注册研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 药物特异性凝血检测在NOAC相关脑出血中仅不频繁使用,非特异性凝血正常不能可靠排除峰值范围浓度。
- 入院时抗凝强度不预测基线血肿体积或后续血肿扩大。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intracerebral hemorrhage (ICH) is a life-threatening complication of non-vitamin K antagonist oral anticoagulants (NOAC). Little is known about the effect of intensity of anticoagulation on NOAC-ICH. We describe the current use of coagulation testing in the emergency setting and explore associations with baseline size and expansion of hematoma as determined in a previous study.
METHODS: Data from the prospective multicenter RASUNOA registry were analyzed. Patients with NOAC-ICH were enrolled between February 2012 and December 2014. Frequency of local test performance of specific (anti-factor Xa tests, diluted thrombin time) and non-specific tests (international normalized ratio (INR), activated partial thromboplastin time (aPTT), thrombin time) was analyzed. The association of anticoagulation intensity at admission with hematoma volume and hematoma expansion was explored.
RESULTS: In 61 NOAC-ICH patients enrolled at 21 centers, drug-specific coagulation testing was performed in 16 cases (26%), and only 29% of centers appeared to use drug-specific tests in NOAC-ICH at all. In some cases, INR and aPTT values were normal despite drug concentrations in the peak range. In patients with available drug-specific concentrations, 50% had drug levels in the peak range at admission. Higher intensity of anticoagulation was not associated with higher hematoma volume at admission or with subsequent hematoma expansion.
CONCLUSION: Drug-specific tests are only infrequently used in NOAC-ICH. Normal results in non-specific coagulation do not reliably rule out peak range concentrations. Anticoagulation intensity at admission does not predict baseline hematoma volume or subsequent hematoma expansion.
参考来源
- Purrucker JC, Rizos T, Haas K, et al. Coagulation Testing in Intracerebral Hemorrhage Related to Non-vitamin K Antagonist Oral Anticoagulants. Neurocrit Care. 2017. PMID: 28477151. doi:10.1007/s12028-017-0403-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。